Register Login

CORCEPT THERAPEUTICS INC (CORT)

SymbolCORT
NameCORCEPT THERAPEUTICS INC
SectorHEALTH CARE
RegionNorth America
IndustryPharmaceutical Preparations
Address101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA 94065
Telephone650.688.8803
Fax—
Email—
Websitehttps://www.corcept.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001088856
Description

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Additional info from NASDAQ:
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

2026-05-05 15:13

📋 Guyer William (Officer) plans to sell 20K shares of CORCEPT THERAPEUTICS INC (at $51.60 each, total $1.0M) Filed: May 05, 2026 | ID: 000016

Read more
2026-05-01 16:30

📋 BELANOFF JOSEPH K (Officer) plans to sell 40K shares of CORCEPT THERAPEUTICS INC (at $46.52 each, total $1.9M) Filed: May 01, 2026 | ID: 000014

Read more
2026-04-30 20:11

(30% Negative) CORCEPT THERAPEUTICS INC (CORT) Reports Q2 2026 Financial Results

Read more
2026-04-30 20:05

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Read more
2026-04-30 20:05

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Read more
2026-04-24 20:30

WILSON JAMES N 🔴 sold 2.0K shares of CORCEPT THERAPEUTICS INC (CORT) Transaction Date: Apr 22, 2026 | Filing ID: 177404

Read more
2026-04-23 20:05

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Read more
2026-04-21 17:21

New Form SCHEDULE 13G/A - CORCEPT THERAPEUTICS INC <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001041885-26-000003 <b>Size:</b> 6 KB

Read more
2026-04-21 17:09

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Read more
2026-04-21 13:00

CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07553663 Evaluating the Pharmacokinetics and Safety of Miricorilant Phase1 Nonalcoholic Steatohepatitis (NASH) Not_Yet_Recruiting 2026-04-30 2026-10-30 ClinicalTrials.gov
NCT07259317 Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pa… Phase2 Adenocarcinoma Recruiting 2026-01-27 2027-07-01 ClinicalTrials.gov
NCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advance… Phase1 Neoplasms Recruiting 2026-01-16 2027-01-01 ClinicalTrials.gov
NCT07240116 Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect … Phase1 Healthy Completed 2025-09-11 2026-03-03 ClinicalTrials.gov
NCT06947304 Evaluation of Miricorilant on Liver Fat in Patients With MASLD Phase1 Nonalcoholic Steatohepatitis (NASH) Recruiting 2025-08-22 2026-05-01 ClinicalTrials.gov
NCT06906341 Relacorilant in Combination With Different Treatment Regimens in Patients With … Phase2 Ovarian Cancer Recruiting 2025-04-11 2026-12-01 ClinicalTrials.gov
NCT06829537 Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resista… — Resistant Hypertension Completed 2025-03-28 2026-01-23 ClinicalTrials.gov
NCT06689254 REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) wi… Phase2 Treatment-resistant PTSD Recruiting 2024-11-15 2026-11-15 ClinicalTrials.gov
NCT06928779 Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant Phase1 Hepatic Impairment Completed 2024-10-08 2024-12-09 ClinicalTrials.gov
NCT06495944 Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in He… Phase1 Healthy Adults Completed 2024-05-31 2024-08-02 ClinicalTrials.gov
NCT06108219 A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic S… Phase2 Nonalcoholic Steatohepatitis (NASH) Active_Not_Recruiting 2023-10-25 2026-09-01 ClinicalTrials.gov
NCT05772169 Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 D… Phase4 Hypercortisolism Completed 2023-03-31 2024-12-18 ClinicalTrials.gov
NCT05712265 Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharma… Phase1 Antipsychotic Induced Weight Gain Completed 2023-01-24 2023-02-23 ClinicalTrials.gov
NCT05407324 Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Phase2 Amyotrophic Lateral Sclerosis Recruiting 2022-11-15 2027-11-01 ClinicalTrials.gov
NCT05257408 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant… Phase3 Ovarian Neoplasm Active_Not_Recruiting 2022-06-29 2026-03-01 ClinicalTrials.gov
NCT05347979 Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein … Phase1 Cushing Syndrome Completed 2022-05-25 2022-07-19 ClinicalTrials.gov
NCT05320146 A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics … — Nonalcoholic Steatohepatitis (NASH) Completed 2022-03-04 2023-07-18 ClinicalTrials.gov
NCT05553470 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of … Phase1 Non-alcoholic Steatohepatitis (NASH) Completed 2022-03-03 2024-09-13 ClinicalTrials.gov
NCT05217758 RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Tre… Phase2 Major Depressive Disorder Completed 2021-12-09 2024-11-12 ClinicalTrials.gov
NCT05117489 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant i… Phase1 Nonalcoholic Steatohepatitis (NASH) Completed 2021-11-23 2024-01-29 ClinicalTrials.gov
NCT04990310 Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-… Phase1 Healthy Completed 2021-08-18 2021-09-20 ClinicalTrials.gov
NCT05003713 Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants Phase1 Healthy Completed 2021-08-03 2023-02-03 ClinicalTrials.gov
NCT04994743 Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Partic… Phase1 Healthy Adults Completed 2021-07-13 2021-09-30 ClinicalTrials.gov
NCT04588688 Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency Phase2 Central Adrenal Insufficiency Terminated 2021-05-05 2021-08-01 ClinicalTrials.gov
NCT04795479 T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization … Phase1 Healthy Completed 2021-01-22 2021-07-13 ClinicalTrials.gov
NCT03823703 Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in … Phase2 Nonalcoholic Steatohepatitis (NASH) Terminated 2020-11-04 2021-04-05 ClinicalTrials.gov
NCT04672512 Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants Phase1 Healthy Completed 2020-10-23 2022-01-17 ClinicalTrials.gov
NCT04373265 Study of Relacorilant in Combination With Pembrolizumab for Patients With Adren… Phase1 Adrenocortical Carcinoma Completed 2020-09-30 2024-01-12 ClinicalTrials.gov
NCT06094738 A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacoril… Phase1 Healthy Completed 2020-09-19 2020-11-16 ClinicalTrials.gov
NCT04524403 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant i… Phase2 Antipsychotic-induced Weight Gain (AIWG) Completed 2020-09-09 2022-08-25 ClinicalTrials.gov
NCT04308590 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Se… Phase3 Hypercortisolism Completed 2020-07-27 2024-09-19 ClinicalTrials.gov
NCT04329949 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metas… Phase3 Metastatic Pancreatic Ductal Adenocarcinoma Terminated 2020-06-30 2022-03-25 ClinicalTrials.gov
NCT04672499 Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations… Phase1 Healthy Completed 2020-04-27 2020-09-07 ClinicalTrials.gov
NCT04249323 Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants Phase1 Healthy Adults Completed 2020-01-27 2020-10-15 ClinicalTrials.gov
NCT06094725 A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics o… Phase1 Hepatic Impairment Completed 2020-01-06 2020-12-14 ClinicalTrials.gov
NCT03818256 A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (C… Phase2 Antipsychotic-induced Weight Gain (AIWG) Completed 2019-12-04 2022-07-06 ClinicalTrials.gov
NCT03776812 Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recu… Phase2 Recurrent Ovarian Cancer Completed 2019-04-05 2023-07-12 ClinicalTrials.gov
NCT03877562 The Effect of CORT118335 on Olanzapine-Induced Weight Gain Phase1 Antipsychotic-induced Weight Gain Completed 2019-04-01 2020-03-25 ClinicalTrials.gov
NCT03697109 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous … Phase3 Cushing Syndrome Completed 2018-11-15 2024-04-15 ClinicalTrials.gov
NCT03674814 Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Pro… Phase1 Prostate Cancer Completed 2018-10-23 2024-06-10 ClinicalTrials.gov
NCT03877952 Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Part… Phase1 Healthy Completed 2018-09-13 2018-11-02 ClinicalTrials.gov
NCT03878264 Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Par… Phase1 Healthy Completed 2018-08-06 2019-03-24 ClinicalTrials.gov
NCT03540836 A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsu… Phase1 Healthy Completed 2018-05-24 2018-07-25 ClinicalTrials.gov
NCT03604198 Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Pati… Phase2 Cushing Syndrome Active_Not_Recruiting 2018-05-07 2026-12-01 ClinicalTrials.gov
NCT03512548 Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure t… Phase1 Healthy Completed 2018-04-10 2019-08-23 ClinicalTrials.gov
NCT03457597 Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure t… Phase1 Healthy Completed 2018-03-06 2018-04-28 ClinicalTrials.gov
NCT03442621 Relacorilant Food Effect Study in Healthy Subjects Phase1 Healthy Completed 2018-01-16 2018-03-09 ClinicalTrials.gov
NCT03437941 Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With … Phase1 Metastatic Castration-Resistant Prostate Cancer Completed 2017-12-15 2023-01-09 ClinicalTrials.gov
NCT03335956 CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Phase1 Healthy Completed 2017-09-21 2018-06-25 ClinicalTrials.gov
NCT03379363 Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for … — Hypercortisolism Terminated 2017-09-18 2018-02-12 ClinicalTrials.gov
NCT03315338 First-in-human Study in Healthy Subjects Phase1 Healthy Completed 2017-09-15 2019-02-22 ClinicalTrials.gov
NCT03258372 Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3… Phase1 Healthy Completed 2017-08-16 2017-11-29 ClinicalTrials.gov
NCT03259542 Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor Phase1 Drug Interaction Potentiation Completed 2017-08-09 2017-12-11 ClinicalTrials.gov
NCT06094790 A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of … Phase1 Healthy Completed 2017-05-18 2017-11-15 ClinicalTrials.gov
NCT02922257 Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before … — Cushing's Syndrome Completed 2016-11-01 2018-10-30 ClinicalTrials.gov
NCT03067376 A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Remov… Phase1 Healthy Completed 2016-08-01 2016-09-01 ClinicalTrials.gov
NCT02804750 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Phase2 Cushing's Syndrome Completed 2016-06-01 2018-09-01 ClinicalTrials.gov
NCT02762981 Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel … Phase1 Solid Tumors Completed 2016-05-23 2020-09-12 ClinicalTrials.gov
NCT06094712 A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation … Phase1 Healthy Completed 2016-04-07 2016-04-27 ClinicalTrials.gov
NCT02642939 Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Meta… Phase2 Non-Small Cell Lung Cancer (NSCLC) Terminated 2015-12-01 2020-10-15 ClinicalTrials.gov
NCT02663609 Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independen… — Cushing's Syndrome Completed 2015-10-01 2017-12-01 ClinicalTrials.gov
NCT03508635 CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Phase1 Healthy Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT02014337 Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Ca… Phase1 Breast Cancer Completed 2014-01-01 2017-12-01 ClinicalTrials.gov
NCT01925092 Mifepristone in Children With Refractory Cushing's Disease Phase3 Cushing's Disease Withdrawn 2013-08-01 — ClinicalTrials.gov
NCT01371565 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Sympt… Phase3 Cushing's Disease Completed 2010-11-01 2012-09-01 ClinicalTrials.gov
NCT00936741 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Phase3 Cushing's Syndrome Completed 2009-07-01 2012-09-01 ClinicalTrials.gov
NCT00796783 A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With … — Cushing's Syndrome Terminated 2009-02-01 — ClinicalTrials.gov
NCT00698022 A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight … Phase1 Healthy Completed 2008-11-01 2009-02-01 ClinicalTrials.gov
NCT00752843 A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics… Phase1 Healthy Subjects Completed 2008-09-01 2008-11-01 ClinicalTrials.gov
NCT00637494 A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Dep… Phase3 Psychotic Depression Terminated 2008-03-01 2014-06-01 ClinicalTrials.gov
NCT00569582 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cus… Phase3 Cushing's Syndrome Completed 2007-12-01 — ClinicalTrials.gov
NCT00455442 A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention o… Phase2 Weight-Gain Prevention Completed 2007-03-01 2007-07-01 ClinicalTrials.gov
NCT00128505 An International Extension Study of Corlux for Recurrent Psychotic Symptoms in … Phase3 Major Depressive Disorder Completed 2005-08-01 2006-11-01 ClinicalTrials.gov
NCT00146523 An International Study of the Safety and Tolerability of Corlux for Psychotic S… Phase3 Major Depressive Disorder Completed 2005-05-01 2006-07-01 ClinicalTrials.gov
NCT00208156 A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in P… Phase3 Depressive Disorder, Major Completed 2005-05-01 2006-11-01 ClinicalTrials.gov
NCT00128479 A United States Study of the Safety and Tolerability of Corlux for Psychotic Sy… Phase3 Major Depressive Disorder Completed 2004-09-01 2007-01-01 ClinicalTrials.gov
NCT00130676 A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depre… Phase3 Major Depressive Disorder Completed 2004-09-01 2006-06-01 ClinicalTrials.gov
NCT00105105 Mifepristone as Adjunctive Therapy in Alzheimer's Disease Phase2 Alzheimer's Disease Terminated 2003-04-01 2005-11-01 ClinicalTrials.gov
Total clinical trials: 78
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Mifepristone Other Phase PHASE3 Cushing's Disease COMPLETED NCT01371565
mifepristone Other Phase PHASE3 Cushing's Disease WITHDRAWN NCT01925092
Mifepristone and Eribulin in combination Other Phase PHASE1 Breast Cancer COMPLETED NCT02014337
Itraconazole 100 MG Other Phase PHASE1 Drug Interaction Potentiation COMPLETED NCT03259542
Mifepristone 300 MG Other Phase PHASE1 Drug Interaction Potentiation COMPLETED NCT03259542
Mifepristone Other Phase PHASE1 Healthy COMPLETED NCT03258372
Relacorilant Other Phase PHASE1 Healthy COMPLETED NCT03457597
Omeprazole Other Phase PHASE1 Healthy COMPLETED NCT03457597
Tolbutamide Other Phase PHASE1 Healthy COMPLETED NCT03457597
Pioglitazone hydrochloride Other Phase PHASE1 Healthy COMPLETED NCT03457597
Metoprolol tartrate Other Phase PHASE1 Healthy COMPLETED NCT03457597
Midazolam hydrochloride Other Phase PHASE1 Healthy COMPLETED NCT03457597
Relacorilant with a moderate breakfast Other Phase PHASE1 Healthy COMPLETED NCT03442621
Relacorilant with a high fat breakfast Other Phase PHASE1 Healthy COMPLETED NCT03442621
Relacorilant Fasted Other Phase PHASE1 Healthy COMPLETED NCT03442621
Placebo oral capsule Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 240mg Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 180mg Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 120mg Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 360mg Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 360mg, fed Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 720mg, fasted Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 360mg, fasted Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 120mg, fasted Other Phase PHASE1 Healthy COMPLETED NCT03335956
Prednisone 25mg, fed Other Phase PHASE1 Healthy COMPLETED NCT03335956
Placebo oral capsule, fed Other Phase PHASE1 Healthy COMPLETED NCT03335956
Pioglitazone 15mg Tablet Other Phase PHASE1 Healthy COMPLETED NCT03335956
Placebo oral capsule, fasted Other Phase PHASE1 Healthy COMPLETED NCT03335956
Prednisone 25mg, fasted Other Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 40mg, fasted Other Phase PHASE1 Healthy COMPLETED NCT03335956
Relacorilant (6x50mg hard-shell capsules) Other Phase PHASE1 Healthy COMPLETED NCT03540836
Relacorilant (3x100 mg hard-shell capsules) Other Phase PHASE1 Healthy COMPLETED NCT03540836
Relacorilant (3x100 mg softgel capsules) Other Phase PHASE1 Healthy COMPLETED NCT03540836
14C-CORT125281 Other Phase PHASE1 Healthy COMPLETED NCT03877952
CORT118335, dose to be determined Other Phase PHASE1 Healthy COMPLETED NCT03315338
Placebo oral capsule Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 1500mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 150mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 900mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 300mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 100mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 375mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 630mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 600mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 675mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 225mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 75mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
Placebo oral suspension Other Phase PHASE1 Healthy COMPLETED NCT03315338
Glucose Other Phase PHASE1 Healthy COMPLETED NCT03315338
Prednisone Oral Tablet Other Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 25 mg Other Phase PHASE1 Healthy COMPLETED NCT03315338
14C-CORT118335 oral Other Phase PHASE1 Healthy COMPLETED NCT03878264
14C-CORT118335 intravenous Other Phase PHASE1 Healthy COMPLETED NCT03878264
CORT118335 Oral Other Phase PHASE1 Healthy COMPLETED NCT03878264
Glucose Other Phase PHASE1 Healthy COMPLETED NCT03508635
Prednisone Other Phase PHASE1 Healthy COMPLETED NCT03508635
Mifepristone Other Phase PHASE1 Healthy COMPLETED NCT03508635
Matching Placebo of CORT125134 Other Phase PHASE1 Healthy COMPLETED NCT03508635
CORT125134 Other Phase PHASE1 Healthy COMPLETED NCT03508635
[14C]-CORT125134 Other Phase PHASE1 Healthy COMPLETED NCT03067376
CORT125134 Other Phase PHASE2 Cushing's Syndrome COMPLETED NCT02804750
Relacorilant 300mg Other Phase PHASE1 Healthy COMPLETED NCT03512548
Itraconazole Other Phase PHASE1 Healthy COMPLETED NCT03512548
Relacorilant 350mg Other Phase PHASE1 Healthy COMPLETED NCT03512548
Placebo Other Phase PHASE1 Antipsychotic-induced Weight Gain COMPLETED NCT03877562
CORT118335 Other Phase PHASE1 Antipsychotic-induced Weight Gain COMPLETED NCT03877562
Olanzapine Other Phase PHASE1 Antipsychotic-induced Weight Gain COMPLETED NCT03877562
Mifepristone Other Phase PHASE2 Non-Small Cell Lung Cancer (NSCLC) TERMINATED NCT02642939
Placebo 150 mg tablets Other Phase PHASE1 Healthy COMPLETED NCT04672499
Miricorilant 150 mg tablets Other Phase PHASE1 Healthy COMPLETED NCT04672499
Miricorilant 300 mg tablets Other Phase PHASE1 Healthy COMPLETED NCT04672499
Moxifloxacin Other Phase PHASE1 Healthy COMPLETED NCT04795479
Placebo to relacorilant Other Phase PHASE1 Healthy COMPLETED NCT04795479
Relacorilant Other Phase PHASE1 Healthy COMPLETED NCT04795479
Placebo matching CORT113176 Other Phase PHASE1 Healthy Adults COMPLETED NCT04994743
CORT113176 Other Phase PHASE1 Healthy Adults COMPLETED NCT04994743
[14C]-CORT113176 Other Phase PHASE1 Healthy COMPLETED NCT04990310
Prednisone Other Phase PHASE1 Healthy Adults COMPLETED NCT04249323
Placebo matching CORT113176 Lipid Capsule Formulation Other Phase PHASE1 Healthy Adults COMPLETED NCT04249323
CORT113176 Lipid Capsule Formulation Other Phase PHASE1 Healthy Adults COMPLETED NCT04249323
Prednisone Other Phase PHASE1 Healthy COMPLETED NCT04672512
Placebo Other Phase PHASE1 Healthy COMPLETED NCT04672512
CORT125329 lipid capsule formulation Other Phase PHASE1 Healthy COMPLETED NCT04672512
Placebo Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) TERMINATED NCT03823703
Miricorilant Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) TERMINATED NCT03823703
Relacorilant with nab-paclitaxel Other Phase PHASE1 Solid Tumors COMPLETED NCT02762981
Relacorilant Other Phase PHASE1 Cushing Syndrome COMPLETED NCT05347979
Dabigatran Etexilate Other Phase PHASE1 Cushing Syndrome COMPLETED NCT05347979
Fluvoxamine Other Phase PHASE1 Antipsychotic Induced Weight Gain COMPLETED NCT05712265
Miricorilant Other Phase PHASE1 Antipsychotic Induced Weight Gain COMPLETED NCT05712265
Prednisone Other Phase PHASE1 Healthy COMPLETED NCT05003713
Placebo matching CORT125236 Other Phase PHASE1 Healthy COMPLETED NCT05003713
CORT125236 Other Phase PHASE1 Healthy COMPLETED NCT05003713
Placebo Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer COMPLETED NCT03437941
Enzalutamide (Xtandi) Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer COMPLETED NCT03437941
CORT125281 Other Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer COMPLETED NCT03437941
No intervention Other Preclinical Cushing's Syndrome COMPLETED NCT02663609
Mifepristone Other Phase PHASE2 Central Adrenal Insufficiency TERMINATED NCT04588688
CORT125134 dose to be determined Other Phase PHASE1 Healthy COMPLETED NCT06094790
CORT125134 250 mg Other Phase PHASE1 Healthy COMPLETED NCT06094790
CORT125134 150 mg Other Phase PHASE1 Healthy COMPLETED NCT06094790
Relacorilant after a low-fat meal Other Phase PHASE1 Healthy COMPLETED NCT06094738
Relacorilant after a high-fat meal Other Phase PHASE1 Healthy COMPLETED NCT06094738
Relacorilant under fasted conditions Other Phase PHASE1 Healthy COMPLETED NCT06094738
Relacorilant Other Phase PHASE1 Hepatic Impairment COMPLETED NCT06094725
CORT125134 Other Phase PHASE1 Healthy COMPLETED NCT06094712
Nab-paclitaxel Other Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma TERMINATED NCT04329949
Relacorilant, 100 mg and 25 mg Other Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma TERMINATED NCT04329949
Pembrolizumab Other Phase PHASE1 Adrenocortical Carcinoma COMPLETED NCT04373265
Relacorilant Other Phase PHASE1 Adrenocortical Carcinoma COMPLETED NCT04373265
Placebo Other Phase PHASE2 Antipsychotic-induced Weight Gain (AIWG) COMPLETED NCT04524403
Miricorlilant Other Phase PHASE2 Antipsychotic-induced Weight Gain (AIWG) COMPLETED NCT04524403
MRI-PDFF Other Preclinical Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05320146
Miricorilant 10 mg Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Miricorilant 50 mg Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Miricorilant 100 mg Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Miricorilant 150 mg Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Placebo Other Phase PHASE2 Antipsychotic-induced Weight Gain (AIWG) COMPLETED NCT03818256
Miricorilant Other Phase PHASE2 Antipsychotic-induced Weight Gain (AIWG) COMPLETED NCT03818256
Placebo Other Phase PHASE2 Treatment-resistant PTSD RECRUITING NCT06689254
Mifepristone 1200 mg daily Other Phase PHASE2 Treatment-resistant PTSD RECRUITING NCT06689254
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05217758
Mifepristone Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05217758
Placebo for mifepristone Other Phase PHASE4 Hypercortisolism COMPLETED NCT05772169
Mifepristone 300 MG [Korlym] Other Phase PHASE4 Hypercortisolism COMPLETED NCT05772169
Miricorilant Other Phase PHASE1 Non-alcoholic Steatohepatitis (NASH) COMPLETED NCT05553470
Dazucorilant Other Phase PHASE1 Hepatic Impairment COMPLETED NCT06928779
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE3 Ovarian Neoplasm ACTIVE_NOT_RECRUITING NCT05257408
Relacorilant 150 mg once daily (QD) Other Phase PHASE3 Ovarian Neoplasm ACTIVE_NOT_RECRUITING NCT05257408
Nab-paclitaxel 80 mg/m^2 Other Phase PHASE3 Ovarian Neoplasm ACTIVE_NOT_RECRUITING NCT05257408
Itraconazole Other Phase PHASE1 Healthy Adults COMPLETED NCT06495944
Dazucorilant Other Phase PHASE1 Healthy Adults COMPLETED NCT06495944
Placebo Other Phase PHASE3 Cushing Syndrome COMPLETED NCT03697109
Relacorilant Other Phase PHASE3 Cushing Syndrome COMPLETED NCT03697109
Placebo Other Phase PHASE3 Hypercortisolism COMPLETED NCT04308590
Relacorilant Other Phase PHASE3 Hypercortisolism COMPLETED NCT04308590
Relacorilant Other Phase PHASE1 Prostate Cancer COMPLETED NCT03674814
Enzalutamide Other Phase PHASE1 Prostate Cancer COMPLETED NCT03674814
Nivolumab Other Phase PHASE1 Neoplasms RECRUITING NCT07276373
Nenocorilant 400 mg Other Phase PHASE1 Neoplasms RECRUITING NCT07276373
Nenocorilant 300 mg Other Phase PHASE1 Neoplasms RECRUITING NCT07276373
Nenocorilant 200 mg Other Phase PHASE1 Neoplasms RECRUITING NCT07276373
Miricorilant Treatment D Drug Phase PHASE1 Healthy COMPLETED NCT07240116
Miricorilant Treatment C Drug Phase PHASE1 Healthy COMPLETED NCT07240116
Miricorilant Treatment B Drug Phase PHASE1 Healthy COMPLETED NCT07240116
Miricorilant Treatment A Drug Phase PHASE1 Healthy COMPLETED NCT07240116
Bevacizumab 10 mg/kg Other Phase PHASE2 Ovarian Cancer RECRUITING NCT06906341
Nab-paclitaxel 80 mg/m^2 Other Phase PHASE2 Ovarian Cancer RECRUITING NCT06906341
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Ovarian Cancer RECRUITING NCT06906341
Nab-paclitaxel Other Phase PHASE2 Recurrent Ovarian Cancer COMPLETED NCT03776812
Relacorilant Other Phase PHASE2 Recurrent Ovarian Cancer COMPLETED NCT03776812
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) RECRUITING NCT06947304
Dazucorilant Other Phase PHASE2 Amyotrophic Lateral Sclerosis RECRUITING NCT05407324
Placebo Other Phase PHASE2 Amyotrophic Lateral Sclerosis RECRUITING NCT05407324
Dazucorilant 150 mg Other Phase PHASE2 Amyotrophic Lateral Sclerosis RECRUITING NCT05407324
Dazucorilant 300 mg Other Phase PHASE2 Amyotrophic Lateral Sclerosis RECRUITING NCT05407324
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Miricorilant Other Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) NOT_YET_RECRUITING NCT07553663
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Gemcitabine 1000 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 100 mg/m^2 Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) Other Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
relacorilant Other Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Placebo (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) Other Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Nivolumab DRUG Phase PHASE1 Neoplasms RECRUITING NCT07276373
Nenocorilant 400 mg DRUG Phase PHASE1 Neoplasms RECRUITING NCT07276373
Nenocorilant 300 mg DRUG Phase PHASE1 Neoplasms RECRUITING NCT07276373
Nenocorilant 200 mg DRUG Phase PHASE1 Neoplasms RECRUITING NCT07276373
Gemcitabine 1000 mg/m^2 DRUG Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Miricorilant Treatment D DRUG Phase PHASE1 Healthy ACTIVE_NOT_RECRUITING NCT07240116
Miricorilant Treatment C DRUG Phase PHASE1 Healthy ACTIVE_NOT_RECRUITING NCT07240116
Miricorilant Treatment B DRUG Phase PHASE1 Healthy ACTIVE_NOT_RECRUITING NCT07240116
Miricorilant Treatment A DRUG Phase PHASE1 Healthy ACTIVE_NOT_RECRUITING NCT07240116
Bevacizumab 10 mg/kg DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT06906341
Mifepristone 1200 mg daily DRUG Phase PHASE2 Treatment-resistant PTSD RECRUITING NCT06689254
Placebo (Cohort B) DRUG Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort B) DRUG Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Placebo (Cohort A) DRUG Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
Miricorilant (Cohort A) DRUG Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING NCT06108219
CORT125134 dose to be determined DRUG Phase PHASE1 Healthy COMPLETED NCT06094790
CORT125134 250 mg DRUG Phase PHASE1 Healthy COMPLETED NCT06094790
CORT125134 150 mg DRUG Phase PHASE1 Healthy COMPLETED NCT06094790
Relacorilant after a low-fat meal DRUG Phase PHASE1 Healthy COMPLETED NCT06094738
Relacorilant after a high-fat meal DRUG Phase PHASE1 Healthy COMPLETED NCT06094738
Relacorilant under fasted conditions DRUG Phase PHASE1 Healthy COMPLETED NCT06094738
Placebo for mifepristone DRUG Phase PHASE4 Hypercortisolism COMPLETED NCT05772169
Mifepristone 300 MG [Korlym] DRUG Phase PHASE4 Hypercortisolism COMPLETED NCT05772169
Fluvoxamine DRUG Phase PHASE1 Antipsychotic Induced Weight Gain COMPLETED NCT05712265
Dazucorilant DRUG Phase PHASE1 Hepatic Impairment COMPLETED NCT06928779
Dazucorilant 150 mg DRUG Phase PHASE2 Amyotrophic Lateral Sclerosis RECRUITING NCT05407324
Dazucorilant 300 mg DRUG Phase PHASE2 Amyotrophic Lateral Sclerosis RECRUITING NCT05407324
Dabigatran Etexilate DRUG Phase PHASE1 Cushing Syndrome COMPLETED NCT05347979
MRI-PDFF OTHER Preclinical Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05320146
Nab-paclitaxel 100 mg/m^2 DRUG Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Relacorilant 150 mg once daily (QD) DRUG Phase PHASE2 Adenocarcinoma RECRUITING NCT07259317
Nab-paclitaxel 80 mg/m^2 DRUG Phase PHASE2 Ovarian Cancer RECRUITING NCT06906341
Miricorilant 10 mg DRUG Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Miricorilant 50 mg DRUG Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Miricorilant 100 mg DRUG Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Miricorilant 150 mg DRUG Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) COMPLETED NCT05117489
Placebo matching CORT125236 DRUG Phase PHASE1 Healthy COMPLETED NCT05003713
CORT125236 DRUG Phase PHASE1 Healthy COMPLETED NCT05003713
Placebo matching CORT113176 DRUG Phase PHASE1 Healthy Adults COMPLETED NCT04994743
CORT113176 DRUG Phase PHASE1 Healthy Adults COMPLETED NCT04994743
[14C]-CORT113176 DRUG Phase PHASE1 Healthy COMPLETED NCT04990310
Moxifloxacin DRUG Phase PHASE1 Healthy COMPLETED NCT04795479
Placebo to relacorilant DRUG Phase PHASE1 Healthy COMPLETED NCT04795479
CORT125329 lipid capsule formulation DRUG Phase PHASE1 Healthy COMPLETED NCT04672512
Placebo 150 mg tablets DRUG Phase PHASE1 Healthy COMPLETED NCT04672499
Miricorilant 150 mg tablets DRUG Phase PHASE1 Healthy COMPLETED NCT04672499
Miricorilant 300 mg tablets DRUG Phase PHASE1 Healthy COMPLETED NCT04672499
Miricorlilant DRUG Phase PHASE2 Antipsychotic-induced Weight Gain (AIWG) COMPLETED NCT04524403
Pembrolizumab DRUG Phase PHASE1 Adrenocortical Carcinoma COMPLETED NCT04373265
Relacorilant, 100 mg and 25 mg DRUG Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma TERMINATED NCT04329949
Placebo matching CORT113176 Lipid Capsule Formulation DRUG Phase PHASE1 Healthy Adults COMPLETED NCT04249323
CORT113176 Lipid Capsule Formulation DRUG Phase PHASE1 Healthy Adults COMPLETED NCT04249323
14C-CORT118335 oral DRUG Phase PHASE1 Healthy COMPLETED NCT03878264
14C-CORT118335 intravenous DRUG Phase PHASE1 Healthy COMPLETED NCT03878264
CORT118335 Oral DRUG Phase PHASE1 Healthy COMPLETED NCT03878264
14C-CORT125281 DRUG Phase PHASE1 Healthy COMPLETED NCT03877952
CORT118335 DRUG Phase PHASE1 Antipsychotic-induced Weight Gain COMPLETED NCT03877562
Olanzapine DRUG Phase PHASE1 Antipsychotic-induced Weight Gain COMPLETED NCT03877562
Miricorilant DRUG Phase PHASE1 Nonalcoholic Steatohepatitis (NASH) RECRUITING NCT06947304
Nab-paclitaxel DRUG Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma TERMINATED NCT04329949
Enzalutamide DRUG Phase PHASE1 Prostate Cancer COMPLETED NCT03674814
relacorilant DRUG Phase PHASE2 Cushing Syndrome ACTIVE_NOT_RECRUITING NCT03604198
Relacorilant (6x50mg hard-shell capsules) DRUG Phase PHASE1 Healthy COMPLETED NCT03540836
Relacorilant (3x100 mg hard-shell capsules) DRUG Phase PHASE1 Healthy COMPLETED NCT03540836
Relacorilant (3x100 mg softgel capsules) DRUG Phase PHASE1 Healthy COMPLETED NCT03540836
Relacorilant 300mg DRUG Phase PHASE1 Healthy COMPLETED NCT03512548
Itraconazole DRUG Phase PHASE1 Healthy Adults COMPLETED NCT06495944
Relacorilant 350mg DRUG Phase PHASE1 Healthy COMPLETED NCT03512548
Prednisone DRUG Phase PHASE1 Healthy COMPLETED NCT05003713
Matching Placebo of CORT125134 DRUG Phase PHASE1 Healthy COMPLETED NCT03508635
Relacorilant DRUG Phase PHASE1 Hepatic Impairment COMPLETED NCT06094725
Omeprazole DRUG Phase PHASE1 Healthy COMPLETED NCT03457597
Tolbutamide DRUG Phase PHASE1 Healthy COMPLETED NCT03457597
Pioglitazone hydrochloride DRUG Phase PHASE1 Healthy COMPLETED NCT03457597
Metoprolol tartrate DRUG Phase PHASE1 Healthy COMPLETED NCT03457597
Midazolam hydrochloride DRUG Phase PHASE1 Healthy COMPLETED NCT03457597
Relacorilant with a moderate breakfast DRUG Phase PHASE1 Healthy COMPLETED NCT03442621
Relacorilant with a high fat breakfast DRUG Phase PHASE1 Healthy COMPLETED NCT03442621
Relacorilant Fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03442621
Placebo DRUG Phase PHASE2 Treatment-resistant PTSD RECRUITING NCT06689254
Enzalutamide (Xtandi) DRUG Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer COMPLETED NCT03437941
CORT125281 DRUG Phase PHASE1 Metastatic Castration-Resistant Prostate Cancer COMPLETED NCT03437941
CORT125281, 240mg DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 180mg DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 120mg DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 360mg DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 360mg, fed DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 720mg, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 360mg, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 120mg, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
Prednisone 25mg, fed DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
Placebo oral capsule, fed DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
Pioglitazone 15mg Tablet DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
Placebo oral capsule, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
Prednisone 25mg, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT125281, 40mg, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT118335, dose to be determined DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
Placebo oral capsule DRUG Phase PHASE1 Healthy COMPLETED NCT03335956
CORT118335, 1500mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 150mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 900mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 300mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 100mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 375mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 630mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 600mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 675mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 225mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 75mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
Placebo oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
Glucose DRUG Phase PHASE1 Healthy COMPLETED NCT03508635
Prednisone Oral Tablet DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
CORT118335, 25 mg DRUG Phase PHASE1 Healthy COMPLETED NCT03315338
Itraconazole 100 MG DRUG Phase PHASE1 Drug Interaction Potentiation COMPLETED NCT03259542
Mifepristone 300 MG DRUG Phase PHASE1 Drug Interaction Potentiation COMPLETED NCT03259542
[14C]-CORT125134 DRUG Phase PHASE1 Healthy COMPLETED NCT03067376
CORT125134 DRUG Phase PHASE1 Healthy COMPLETED NCT06094712
Relacorilant with nab-paclitaxel DRUG Phase PHASE1 Solid Tumors COMPLETED NCT02762981
No intervention OTHER Preclinical Cushing's Syndrome COMPLETED NCT02663609
Mifepristone and Eribulin in combination DRUG Phase PHASE1 Breast Cancer COMPLETED NCT02014337
Cushing's syndrome confirmation DRUG Preclinical Cushing's Syndrome TERMINATED NCT00796783
mifepristone + fluvastatin DRUG Phase PHASE1 Healthy Subjects COMPLETED NCT00752843
Mifepristone-matched placebo DRUG Phase PHASE1 Healthy COMPLETED NCT00698022
Risperidone-matched placebo DRUG Phase PHASE1 Healthy COMPLETED NCT00698022
Risperidone DRUG Phase PHASE1 Healthy COMPLETED NCT00698022
placebo DRUG Phase PHASE3 Psychotic Depression TERMINATED NCT00637494
matching placebo DRUG Phase PHASE3 Major Depressive Disorder COMPLETED NCT00130676
Mifepristone DRUG Phase PHASE2 Major Depressive Disorder COMPLETED NCT05217758
mifepristone 1200 mg DRUG Phase PHASE3 Major Depressive Disorder COMPLETED NCT00128479
mifepristone 600 mg DRUG Phase PHASE3 Major Depressive Disorder COMPLETED NCT00128479
mifepristone matched placebo DRUG Phase PHASE3 Major Depressive Disorder COMPLETED NCT00128479
mifepristone DRUG Phase PHASE3 Cushing's Disease WITHDRAWN NCT01925092
Total products: 376